Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision

TheFly reported connected April 13 that Jefferies chopped its standing connected REPL from Buy to Hold and reduced its terms people sharply to $2 from $13. The steadfast cited accrued uncertainty pursuing the FDA’s implicit effect missive regarding RP1. According to management, further improvement of RP1 volition not proceed unless an accelerated support pathway is secured wrong the expected timeframe. Jefferies indicated that the setback creates a much hard outlook for the programme and limits near-term visibility. The steadfast besides noted that the company’s wide improvement trajectory present appears little clear, with aboriginal advancement babelike connected regulatory outcomes and solution of existent support concerns.

On April 10, Replimune Group, Inc. (NASDAQ:REPL) stated that the FDA’s implicit effect missive reflects positions that disagree from those communicated successful earlier regulatory interactions, peculiarly the September 2025 Type A meeting. The institution noted that a caller reappraisal squad handled the resubmission and did not prosecute straight contempt offers for discussion.

It highlighted that anterior bureau feedback had supported aspects of the RP1 positive nivolumab dataset, including acknowledgment of challenges successful moving a randomized power limb and acceptance of definite grounds frameworks. REPL besides pointed to earlier regulatory discussions suggesting a single-arm dataset could beryllium capable nether accelerated support conditions, contrasting with the aboriginal reappraisal result and concerns raised successful the CRL.

Replimune Group, Inc. (NASDAQ:REPL) is simply a clinical-stage biotechnology institution focused connected processing oncolytic immunotherapies for cancer. Its proprietary RPx level is designed to stimulate the immune strategy to admit and destruct tumor cells, either unsocial oregon successful operation with different treatments.

While we admit the imaginable of REPL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest successful According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.